Antiproliferative effects of γ-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action

Journal of International Medical Research

Volumn 41, Issue 4, 2013, Pages 1017-1026

  Hu, Jiasheng ^a   Zhu, Xiongpeng ^a   Lu, Quanyi ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

secretase inhibitor; Multiple myeloma; Notch signalling pathway; phosphoinositide 3 kinase Akt pathway; proliferation

Indexed keywords

GAMMA SECRETASE INHIBITOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; JAGGED1; JAGGED2; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NOTCH1 RECEPTOR; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ELECTROPHORESIS; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MORPHOGENESIS; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84887375319     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513485912     Document Type: Article

References (38)

1. Balakumaran A,Robey PG,Fedarko N,et al.Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis.Expert Rev Mol Diagn. 2010;10:465-480.
2. Klein B,Seckinger A,Moehler T,et al.Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.Recent Results Cancer Res. 2011;183:39-86.
3. Podar K,Chauhan D,Anderson KC.Bone marrow microenvironment and the identification of new targets for myeloma therapy.Leukemia. 2009;23:10-24.
4. Nefedova Y,Landowski TH,Dalton WS.Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.Leukemia. 2003;17:1175-1182.
5. Houde C,Li Y,Song L,et al.Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines.Blood. 2004;104:3697-3704.
6. Artavanis-Tsakonas S,Muskavitch MA.Notch: the past, the present, and the future.Curr Top Dev Biol. 2010;92:1-29.
7. Artavanis-Tsakonas S,Rand MD,Lake RJ.Notch signaling: cell fate control and signal integration in development.Science. 1999;284:770-776.
8. Osborne B,Miele L.Notch and the immune system.Immunity. 1999;11:653-663.
9. Miele L,Osborne B.Arbiter of differentiation and death: notch signaling meets apoptosis.J Cell Physiol. 1999;181:393-409.
10. Kopan R.Notch: a membrane-bound transcription factor.J Cell Sci. 2002;115:1095-1097.
11. Miele L.Notch signaling.Clin Cancer Res. 2006;12:1074-1079.
12. Groth C,Fortini ME.Therapeutic approaches to modulating Notch signaling: current challenges and future prospects.Semin Cell Dev Biol. 2012;23:465-472.
13. Tay K,Dunleavy K,Wilson WH.Novel agents for B-cell non-Hodgkin lymphoma: science and the promise.Blood Rev. 2010;24:69-82.
14. Xu X,Zhao Y,Xu M,et al.Activation of Notch signal pathway is associated with a poorer prognosis in acute myeloid leukemia.Med Oncol. 2011;28:S483-489.
15. Leethanakul C,Patel V,Gillespie J,et al.Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays.Oncogene. 2000;19:3220-3224.
16. Jundt F,Anagnostopoulos I,Förster R,et al.Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma.Blood. 2002;99:3398-3403.
17. Weijzen S,Rizzo P,Braid M,et al.Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells.Nat Med. 2002;8:979-986.
18. Nefedova Y,Sullivan DM,Bolick SC,et al.Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy.Blood. 2008;111:2220-2229.
19. Lu Q,Lin X,Feng J,et al.Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways.J Hematol Oncol. 2008;1:6-6.
20. Jundt F,Pröbsting KS,Anagnostopoulos I,et al.Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells.Blood. 2004;103:3511-3515.
21. Nefedova Y,Cheng P,Alsina M,et al.Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines.Blood. 2004;103:3503-3510.
22. Weng AP,Nam Y,Wolfe MS,et al.Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling.Mol Cell Biol. 2003;23:655-664.
23. Skrtić A,Korać P,Krišto DR,et al.Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.Hum Pathol. 2010;41:1702-1710.
24. Shih IeM, Wang TL.Notch signaling, gamma-secretase inhibitors, and cancer therapy.Cancer Res. 2007;67:1879-1882.
25. Chadwick N,Zeef L,Portillo V,et al.Identification of novel Notch target genes in T cell leukaemia.Mol Cancer. 2009;8:35-35.
26. Joshi I,Minter LM,Telfer J,et al.Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases.Blood. 2009;113:1689-1698.
27. Curry CL,Reed LL,Golde TE,et al.Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells.Oncogene. 2005;24:6333-6344.
28. Tanaka M,Setoguchi T,Hirotsu M,et al.Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation.Br J Cancer. 2009;100:1957-1965.
29. Fan X,Mikolaenko I,Elhassan I,et al.Notch1 and notch2 have opposite effects on embryonal brain tumor growth.Cancer Res. 2004;64:7787-7793.
30. Wang M,Wu L,Wang L,et al.Down-regulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780.Biochem Biophys Res Commun. 2010;393:144-149.
31. Wang Z,Li Y,Banerjee S,et al.Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways.J Cell Biochem. 2010;109:726-736.
32. Kondratyev M,Kreso A,Hallett RM,et al.Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.Oncogene. 2012;31:93-103.
33. Rasul S,Balasubramanian R,Filipović A,et al.Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells.Br J Cancer. 2009;100:1879-1888.
34. Liu P,Cheng H,Roberts TM,et al.Targeting the phosphoinositide 3-kinase pathway in cancer.Nat Rev Drug Discov. 2009;8:627-644.
35. Abedini MR,Muller EJ,Bergeron R,et al.Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.Oncogene. 2010;29:11-25.
36. McBride SM,Perez DA,Polley MY,et al.Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.J Neurooncol. 2010;97:33-40.
37. Liu ZJ,Xiao M,Balint K,et al.Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression.Cancer Res. 2006;66:4182-4190.
38. Palomero T,Dominguez M,Ferrando AA.The role of the PTEN/AKT pathway in NOTCH1-induced leukemia.Cell Cycle. 2008;7:965-970.